2019
Our friends at GARDP are calling upon the global community to support its goal to develop and deliver five new treatments by 2025 in response to the growing burden of antibiotic resistant infections.
Antibiotics have radically transformed our world by making previously incurable illnesses treatable. As a result, not only has our wellbeing significantly improved, but millions of lives have been saved.
2019
We are delighted to see an article on children’s antibiotics, co-authored by GARDP R&D Director, Dr Seamus O’Brien, Penta’s Chief Scientific Officer, Prof. Theo Zakoutlis and Prof. Mike Sharland, from St. George’s, University of London, published in AMR Control, as governments have been discussing AMR at the World Health Assembly.
In R&D for children’s antibiotics: a wake-up call the authors explain how AMR has a disproportionate effect on children,
2019
On Tuesday 24th September, the Infection Prevention Disease Society event IP2019 in Liverpool will host the one-day conference: Infection Prevention in Paediatrics: ‘Hand in Hand’- working together for children.
This important event will address paediatric care across areas such as Infection Prevention & Control, Tissue Viability & Wound Care, IV and Infectious Diseases. The programme has been tailored towards all paediatric healthcare workers including: IV Specialist Nurses,
2019
Penta have joined forces with GARDP (The Global Antibiotic Research & Development Partnership) to tackle drug-resistant infections in children. Our strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines.
Globally, more than three million childhood deaths result from infectious diseases,
2019
Penta project manager Davide Bilardi, together with other NeoObs project partners, recently visited the neonatal units of the Santa Casa Hospital in São Paolo and the Clinical Research Unit of University of São Paolo in Ribeirao Preto. The visit occurred in the last week of January and was an opportunity to strengthen the relationship with new partner sites involved in the activities of this study. NeoObs is an observational study focused on understanding sepsis in newborns and current antibiotic prescribing practices.
2019
We are pleased to celebrate the milestone achievement of the randomisation of 200 participants in the NeoVanc project. Congratulations to all the NeoVanc team!
A special mention needs to be made on the great effort of investigators, co-investigators and all researchers at recruiting sites involved in this key study on the use of Vancomycin in paediatrics. We look forward to continuing our work together towards reaching the project target of 300 evaluable participants and we wish the NeoVanc team the best of luck!
2018